8:00

Registration, Refreshments & Networking

Chair of Session:  Peter Hirst, Head Of BD, Merxin Ltd

9:30

Welcome To SMI.London 2026 - The SMI Year In Review
What Is The Latest Gossip?

Philippe Rogueda, CBO Merxin Ltd

10:00

Targeted Delivery Enabled By Rayleigh SMIs

Hao-Ying Li, Researcher, King’s College London

• Elucidate the essence of the formation of LNP-mRNAs.

• Insights into the changes of LNP-mRNAs under shear stress (theoretically explain why VMN does not work)

• Soft mists for the delivery of LNP-mRNAs to targeted regions in nasal cavity

• Soft mists for the delivery of LNP-mRNAs to the lungs

• Some corrigendum of concepts

10:30

Coffee break, Exhibition & Networking

11:00

PALM, A Tuneable Low-Stress SMI Platform

Tuncay Alan, Associate Professor, Monash University

• Nozzle-free oscillating microchannel technology generates low-velocity (<1 m/s), low-shear aerosols

• Tuneable droplet size and plume characteristics deliver precise aerosol performance, achieving 93% fine particle fraction (NGI)

• The system delivers proteins and viscous formulations while preserving biological activity 

• Adaptive dosing enables on-demand adjustment of output and droplet velocity, from low to high-throughput delivery 

• Fully integrated handheld device combining microfluidics, actuation and electronic control, with cartridge-based delivery, designed for partner evaluation and scalable, low-cost manufacturing

11:30

Digital Twin Evaluates Breath Actuated SMI Lung Dose

Nicolas Schwenck, Head of BD & Partnerships, Ebenbuild GmbH

• Simulation of aerosol transport and regional deposition using CT-derived airway geometries and a physics-based whole-lung model

• Quantification of the local dose at the site of action across lung regions for pharmacopeial breathing assumptions and measured real-world breathing profiles

• Integration of in vitro aerosol characteristics from different aerosol-generating device classes: SMI, DPI and pMDI

• Device-class dependent differences in regional lung deposition identified across breathing patterns, enabling extension of the framework to virtual cohort studies for in silico evaluation of inhaled drug delivery

12:00

Characterising SMI aerosol performance in vitro

Ben Forbes, Professor of Pharmaceutics, King’s College London

• Nasal Deposition

• Alberta Idealised Nasal Inlet

• Aerodynamic Particle Size Distribution

• Next Generation Impactor

• Effect of flow rate & Temperature

12:15

Lunch, Exhibition & Networking

Chair of Session:  Francesca Buttini, Associate Professor, University of Parma

13:30

How to Tune a Nasal SMI Product

Laleh Golshahi, PhD, Associate Professor, VCU & Founder & CEO, 3DInhale

• Existing pre-clinical tools fail to capture combined device–technique–breathing effects. 

• Anatomical nasal casts enable controlled multi-parameter deposition evaluation. 

• Spray design and plume geometry dominate deposition over breathing. 

• Administration orientation drives regional coverage; generalized guidance is achievable. 

• Olfactory targeting likely requires device-specific, not generalized, strategies.

14:00

Improving ICU aerosol therapy with soft mist technology

Madeline Zhang, PhD Researcher, University of Amsterdam

• On-demand absolute humidification using a soft mist nozzle decouples gas flow humidification from heating, while maintaining clinical safety thresholds

• Improved drug delivery efficiency by reducing undesired deposition in breathing circuits through partial evaporation of drug droplets, for both high-flow nasal cannula (HFNC) therapy and invasive mechanical ventilation (IMV)

• Bench measurements translated to regional respiratory tract deposition using simulations, providing insights into effective dose in target regions

• Pulmonary diseases alter regional deposition, highlighting the potential need for adaptive aerosol therapy strategies

14:30

An SMI delivery platform for siRNA therapeutics

Chantelle Ahlenstiel, Professor,  Kirby Institute, UNSW Sydney

• Optimised LNP formulation for respiratory delivery of siRNA

• Targeting the nasopharynx for upper respiratory tract virus infections

• Advancing respiratory models with ALI-cultures and live virus challenge

• Safety and antiviral efficacy of siRNA-LNP in a SARS-CoV-2 mouse model

• Platform technology broadly applicable for respiratory disease

15:00

Coffee break, Exhibition & Networking

Chair of Session:  Ayca Pekoz, Professor, Istanbul University

15:30

Building The Future: Inhaled Therapies In Development

Darragh Murnane, Royal Society Industrial Fellow, Merxin Ltd

• A range of novel therapeutic modalities are emerging for respiratory delivery

• There are few examples of novel modalities with regulatory approvals to guide the pathway for development 

• This talk will examine the types of therapeutic modalities currently in clinical trials and assess progression success through translational phases 

• We will identify the range of therapeutic modalities which inhaler device specialists can expect to manage in the coming years.

16:00

The Ensifentrine Story: A Bifunctional Therapy For Respiratory Diseases

Prof. Clive P. Page OBE, Professor of Pharmacology, King’s College London

• The need for new therapies for asthma and COPD

• Will discuss the discovery and development of ensifentrine

• First in class inhaled "bifunctional" drug combining anti-inflammatory and bronchodilator activity in a single molecule

• Positioning of ensifentrine in the treatment of COPD

• Future developments

16:30

Panel Discussion & final remarks

17:00

Close of the day